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Background
Development of mucosal adjuvants to elicit immunity in
the female genital tract may have important implications
for the development of vaccines to counter sexually trans-
mitted infections. We have recently documented the vagi-
nal adjuvant effect of the TLR9 agonist CpG-ODN, and a
non-TLR targeting molecule α galactosylceramide (α-Gal-
Cer), an invariant natural killer T cell ligand, for induction
of protective immunity in the murine female genital tract.
Methods
This study was undertaken to examine correlate of adju-
vanticity in the vagina and the draining lymph nodes as
well as inflammatory response elicited in the murine
vagina following local administration of these two classes
of vaginal adjuvants.
Results
Real time PCR array analysis of 84 genes involved in
inflammation and initiation of immune response
revealed that a group of 13 common cytokine genes are
activated in the vagina within 24 h after vaginal adminis-
tration of either CpG-ODN or α-GalCer, including Ccl2,
Ccl7, Ccl12, Ccl19, Ccl20, Ccl22, Cxcl1, Cxcl5, IL-10 and
the Th1-inducing molecules IFN-γ, Cxcl9, Cxcl10 and
Cxcl11. Some of these genes were also expressed in the
genital lymph nodes. Of note, up-regulation in gene
expression of inflammatory cytokines TNF and IL-1β that
are involved in overt inflammation was exclusively
observed in the vagina of the CpG-ODN treated mice. This
was concomitant with a higher degree of inflammation in
the vaginal mucosa of the CpG-ODN group compared to
that of the α-GalCer group.
Conclusion
In conclusion, these results indicate that there is a group
of common genes that correlate with the adjuvanticity of
CpG-ODN and α-GalCer in the vagina and the draining
lymph nodes, and that the non TLR/MyD88 targeting
adjuvant α-GalCer induces less local inflammatory reac-
tions in the murine vagina compared to the TLR/MyD88
targeting adjuvant CpG-ODN. These findings may have
implications for the development of mucosal adjuvants to
counter sexually transmitted infections.
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